Rifaat El-Mallakh, MD
Psychiatry · Louisville, KYNPI 1174595300
Payments from drug & device makers
Across 1,849 payments — averaging $914.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$762K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$348K
- Johnson & Johnson$126K
- Vanda Pharmaceuticals Inc.$106K
- Axsome Therapeutics, Inc.$78K
- Indivior Inc.$51K
- plus $219K from 21 others
Across 6 payments — averaging $197.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 823 | $761,996 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 325 | $348,209 |
| Johnson & Johnson | 158 | $125,956 |
| Vanda Pharmaceuticals Inc. | 103 | $106,375 |
| Axsome Therapeutics, Inc. | 54 | $77,974 |
| Indivior Inc. | 99 | $50,941 |
| Sumitomo Pharma America, Inc. | 26 | $46,277 |
| Alkermes, Inc. | 38 | $41,513 |
| Teva Pharmaceuticals USA, Inc. | 32 | $27,096 |
| Janssen Research & Development, LLC | 11 | $19,852 |
| Eisai Inc. | 15 | $13,900 |
| Idorsia Pharmaceuticals US Inc | 19 | $12,885 |
| Neurocrine Biosciences, Inc. | 26 | $12,857 |
| AbbVie(2 entities) | 21 | $9,742 |
| Noven Pharmaceuticals, Inc. | 9 | $9,028 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 11 | $8,165 |
| F. Hoffmann-la Roche AG | 1 | $6,000 |
| E.r. Squibb & Sons, L.L.C. | 9 | $3,770 |
| Sunovion Pharmaceuticals Inc. | 51 | $3,254 |
| Biogen | 2 | $3,198 |
| Lundbeck LLC | 5 | $312 |
| Bioxcel Therapeutics, Inc. | 3 | $289 |
| Sage Therapeutics, LLC | 2 | $188 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $112 |
| Janssen Scientific Affairs, LLC | 2 | $99 |
| Novo Nordisk | 1 | $86 |
| Boehringer Ingelheim | 1 | $85 |
How this compares
$1,690,161 in reported general payments places this provider in the 95th percentile of 348 psychiatry providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Louisville
- Robert StewartLouisville$651K
- Ali FarooquiLouisville$393K
- Stephanie HallLouisville$106K
- Kelly ClarkLouisville$14K
- Michael HarrisLouisville$13K
- Yelena VaninaLouisville$12K
- Mohamed KhodeirLouisville$9K
- Kevin BaysLouisville$9K
- Terry HaganLouisville$8K
- Ronald McGavicLouisville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.